Nevertheless, it has been indicated that PRO-C3 is a more dynamic marker of fibrogenesis compared to ELF, shown in several clinical trial studies of NASH or primary sclerosing cholangitis (PSC), where reduction of PRO-C3 were greater compared with ELF and also the PIIINP component alone, during treatment of patients with potential anti-fibrotic therapies.40 This evidence concerns the gene C3 and metabolic dysfunction-associated steatohepatitis.